Search
The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.
Searched for: metastatic breast cancer. 17 results shown below.
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Complete title: A Phase I Dose Escalation Trial of Alpha-tocopheryloxyacetic Acid (alpha-TEA) in Patients with Treatment Refractory HER2+ Metastatic Breast Cancer
Principal Investigator: William Gwin
Study Number: 8790
Phase: I
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Complete title: Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Principal Investigator: Li-Ming Fang
Study Number: 9701
Phase: III
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
Complete title: Expanded Access Protocol with ABT-888 (Veliparib) in Patients with Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer
Principal Investigator: Jennifer Specht, MD
Study Number: 9763
Phase: N/A
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
Complete title: A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination with Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients with HER2-Positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab: The "AVIATOR" Study
Principal Investigator: Natasha Hunter
Study Number: RG1004199
Phase: II
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
Complete title: A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Principal Investigator: Natasha Hunter
Study Number: RG1006860
Phase: I/II
Olaparib In Metastatic Breast Cancer
Complete title: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes "Olaparib Expanded"
Principal Investigator: Shaveta Vinayak
Study Number: TBCRC048
Phase: II
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (T-DM1)
Complete title: A Randomized Phase II Study to Evaluate Efficacy of T-DM1 With or Without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer
Principal Investigator: Jennifer Specht, MD
Study Number: Palbo T-DM1
Phase: II
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
Complete title: [F18] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer
Principal Investigator: Hannah Linden, MD
Study Number: 9594
Phase: II
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Complete title: FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE
Principal Investigator: Jennifer Specht, MD
Study Number: RG1007840
Phase: II
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Complete title: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Principal Investigator: Rachel Yung
Study Number: S1501
Phase: III
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Complete title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer
Principal Investigator: Jennifer Specht, MD
Study Number: 20131069
Phase: I
A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Complete title: A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS
Principal Investigator: Kit Wong
Study Number: 20171486
Phase: I
A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Complete title: A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFICATION OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN-2 (VBIR-2) (PF-06936308) FOR ADVANCED NON-SMALL CELL LUNG CANCER AND METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Principal Investigator: Nora Disis, MD
Study Number: 20181578
Phase: I
A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies (REVEAL)
Complete title: A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination with NKTR-214 and in Combination with NKTR-214 plus Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies
Principal Investigator: Shailender Bhatia, MD
Study Number: RG1004346
Phase: I/II
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Complete title: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Principal Investigator: Shaveta Vinayak
Study Number: RG1005141
Phase: I/II
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)
Complete title: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Abemaciclib to Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Principal Investigator: Kalyan Banda
Study Number: RG1007753
Phase: I
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (mBC)
Complete title: A Phase 1/2, open-label, dose escalation, and cohort expansion clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ARV-471 in patients with ER+/HER2- locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting
Principal Investigator: Natasha Hunter
Study Number: RG1121177
Phase: I/II